PARP-14 Promotes Survival of Mammalian α but Not β Pancreatic Cells Following Cytokine Treatment
PARP-14 Promotes Survival of Mammalian α but Not β Pancreatic Cells Following Cytokine Treatment Floriana D'Angeli1, Marina Scalia2, Matilde Cirnigliaro2, Cristina Satriano3, Vincenza Barresi1, Nicolò Musso1, Angela Trovato-Salinaro1, Davide Barbagallo2, Marco Ragusa2, Cinzia Di Pietro2, Michele Purrello2 and Vittoria Spina-Purrello1* 1Department of Biomedical and Biotechnological Sciences, Section of Medical Biochemistry, University of Catania, Catania, Italy 2Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics, University of Catania, Catania, Italy 3Department of Chemical Sciences, University of Catania, Catania, Italy PARP-14 (poly-ADP Ribose Polymerase-14), a member of the PARP family, belongs to the group of Bal proteins (B Aggressive Lymphoma). PARP-14 has recently appeared to be involved in the transduction pathway mediated by JNKs (c Jun N terminal Kinases), among which JNK2 promotes cancer cell survival. Several pharmacological PARP inhibitors are currently used as antitumor agents, even though they have also proved to be effective in many inflammatory diseases. Cytokine release from immune system cells characterizes many autoimmune inflammatory disorders, including type I diabetes, in which the inflammatory state causes β cell loss. Nevertheless, growing evidence supports a concomitant implication of glucagon secreting α cells in type I diabetes progression. Here, we provide evidence on the ...
We present a rare case of hemichorea associated with a hemorrhagic stroke in the contralateral striatum.
Antipsychotic medications are a vital part of controlling psychosis in schizophrenic patients. However, when those patients live in nursing facilities, we are obligated by CMS to undertake gradual dose reductions of antipsychotic medication if possible. Sometimes, these efforts are successful and sometimes they fail. Antipsychotic medications have many side effects, including sedation, diabetes, hyperlipidemia, weight gain, motor rigidity, impaired gait, and falls. Monitoring of blood glucose, lipids, and extrapyramidal symptoms is mandatory.
Management of diabetes in post-acute settings needs special considerations. Hypoglycemia in the skilled nursing and rehabilitation facilities can lead to readmissions and complications including falls. Current EHR care-sets may not make a distinction between hospital and post-acute settings regarding diabetes management. The current diabetes management care-set in the EHR of our large healthcare system includes checking the blood sugar QID/AC/HS (before breakfast, lunch and dinner, and bedtime).
CONCLUSIONS.: This study provided an atlas of genetic correlations between psychiatric disorders and plasma proteome, providing novel clues for pathogenetic and biomarkers, therapeutic studies of psychiatric disorders. PMID: 32093803 [PubMed - in process]
CONCLUSIONS.: Our results confirm orbitofrontal structural deficits in BPD, while providing a framework and preliminary findings on identifying structural correlates of symptom dimensions in BPD, especially with dorsolateral and orbitofrontal cortices. PMID: 32093800 [PubMed - in process]
CONCLUSIONS.: Despite sharing a lower IQ and a higher prevalence of psychiatric disorders, brain abnormalities in BDo appear less pronounced (but are not absent) than in SZo. Lower ICV in SZo implies that familial risk for schizophrenia has a stronger association with stunted early brain development than familial risk for bipolar disorder. PMID: 32093799 [PubMed - in process]
Authors: Lee YM, Park SH, Lee DH Abstract OBJECTIVE: The aim of this paper is to propose a new hypothesis for the role of lipophilic chemical mixtures stored in adipose tissue in the development of dementia. Specifically, we present how the dynamics of these chemicals can explain the unexpected findings from the Action for Health in Diabetes (Look AHEAD) study, which failed to show long-term benefits of intentional weight loss on cognition, despite substantial improvements in many known risk factors for dementia. Moreover, we discuss how the role of obesity in the risk of dementia can change depending on the dynami...
Hi guys, I'm trying to gauge where I stand and am very confused due to my weird background. I took the MCAT in Jan and received a 524, but my GPAs are on the lower end. I am AA URM. GPA: 3.66c, 3.73s, 1 year 4.0 at end || 3.5 masters, 3.5 PhD first year (left see below) MCAT: 524 || Balanced, first take State: CA Race: URM, AA Clinical Volunteering: 250 hours - general hospital volunteer pulm unit 200 hours - driver for american cancer society patients 280... 3.66 cGPA, 3.73sGPA, 524 MCAT URM
Publication date: Available online 25 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Tony Kirby
More News: Allergy | Allergy & Immunology | Autoimmune Disease | Biochemistry | Biology | Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Diabetes | Diabetes Type 2 | Education | Endocrinology | Environmental Health | Gastroschisis Repair | Genetics | Germany Health | Grants | Insulin | Italy Health | Lymphoma | Men | Merck | Molecular Biology | Myeloma | Nanotechnology | Neurology | Neuroscience | Pancreas | Pancreatic Cancer | Penicillin | PET Scan | Physiology | Statistics | Students | Study | Universities & Medical Training